Hematuria Risk with Antithrombotic Agents

Patient Risk Factors

Higher doses of enoxaparin (80 mg or greater) are associated with a 4.1-fold increased risk of bleeding complications compared to lower doses (40 mg) 1
Minor hematuria is statistically more frequent among patients taking aspirin than in control groups (p=0.001, OR 1.36) 1
Clopidogrel causes irreversible platelet inhibition, and while it may not directly cause mucosal injury, it is associated with an increased risk of bleeding including hematuria 2
Patients on dual antiplatelet therapy with aspirin and clopidogrel have a 70% increased relative risk of bleeding compared to monotherapy 2

The American Heart Association recommends continuing aspirin and temporarily withholding clopidogrel for patients with active hematuria on dual antiplatelet therapy 4
For patients on enoxaparin with serious bleeding, consider temporarily interrupting therapy until hemostasis is achieved 4

Advanced age significantly increases the absolute risk of bleeding with antithrombotic agents 3
History of previous bleeding or peptic ulcer disease is the strongest risk factor for bleeding in patients taking antiplatelet agents 3
Concurrent use of NSAIDs or steroids with antithrombotic agents further increases bleeding risk 3, 5